Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Anika Therapeutics Inc. (ANIK) vs Organogenesis (ORGO)

Anika Therapeutics Inc. and Organogenesis are both Drug Manufacturers Specialty & Generic companies. Anika Therapeutics Inc. is the larger, with a market value of $270.7M against $207.1M — 1.3× the size. Organogenesis grew revenue faster over the last twelve months: 6.50% against 5.33%. Anika Therapeutics Inc. has the higher net margin (−3.14% vs −22.2%) and the higher return on invested capital (−3.24% vs −20.0%). Across the 20 metrics below, Organogenesis leads on 12 and Anika Therapeutics Inc. on 8.

Valuation

Metric ANIK ORGO Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 2.25 0.39 2.25
P/B 1.98 1.22 1.90
Price to free cash flow 483.15 8.64 16.54
EV/EBITDA 508.54 n/m 12.29
EV/Sales 2.16 0.33 2.56
Earnings yield (1.28%) (60.71%) (2.99%)
Free cash flow yield 0.21% 11.57% 0.00%

Profitability

Metric ANIK ORGO Drug Manufacturers Specialty & Generic median
Gross margin 62.16% 70.35% 53.94%
Operating margin (4.24%) (7.84%) 0.00%
Net margin (3.14%) (22.23%) 0.00%
Free cash flow margin 0.47% 4.56% 0.00%
Return on equity (2.66%) (53.31%) (0.40%)
Return on assets (2.04%) (23.44%) (3.32%)
Return on invested capital (3.24%) (19.97%) 0.00%

Growth

Metric ANIK ORGO Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 5.33% 6.50% 10.01%
EPS growth (last fiscal year) 80.16% 1,600.00% —
Revenue growth, 5-year CAGR (2.86%) 10.77% 6.74%
Net income growth, 5-year CAGR 0.00% 3.04% 0.00%

Health

Metric ANIK ORGO Drug Manufacturers Specialty & Generic median
Debt to equity 0.00 0.07 0.05
Current ratio 4.48 3.52 2.31
Net debt to EBITDA 10.80 (1.14) 0.85

Dividend

Metric ANIK ORGO Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric ANIK ORGO Drug Manufacturers Specialty & Generic median
Market cap 270.74m 207.13m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack